Newsletter Subject

Daily Headlines: Stem Cell Tx May Halt MS Disability Progression

From

medpagetoday.com

Email Address

daily.headlines@broadcaster3.medpagetoday.com

Sent On

Wed, Feb 22, 2017 12:06 PM

Email Preheader Text

Daily Headlines February 22, 2017 CME/CE Additional Resources Industry Resources [Repatha? MDs: He

Daily Headlines February 22, 2017 [Stem Cell Tx May Halt MS Disability Progression]( [Pearls from: Ronald Petersen, MD, PhD]( [Projection: South Korea to Lead World in Life Expectancy by 2030]( CME/CE [Insurance Pay Varies by Practice Type: Physicians Practice]( [Policy Papers on ACA Repeal: Many Question, Few Answers]( Additional Resources [Diagnosis and Treatment of Relapsed Myeloma]( [AML: Beware of Pre-leukemic Clones Surviving Chemotherapy]( [Support for Omitting ALND in Early Breast Cancer]( Industry Resources [Repatha™ (evolocumab) MDs: Help Get Patients Started on Repatha™]( [Myelomatosis A Treatment Option For Previously Treated Multiple Myeloma. HCP Site.]( [Multiple Myeloma HCP Site Learn about a Treatment Option For Multiple Myeloma Relapses]( Recent Headlines [A Patient's Journey: The First That Was Almost Forgotten]( [Negative Trial in Metastatic RCC Still Generates Buzz]( [Weak Thigh Muscles Increase Knee OA Risk in Women]( CME/CE [Oncology Pioneer Jim Holland Continues Exploring New Frontiers]( [HIV Patients Who Quit Smoking Lower Cancer Risk]( CME/CE ADVERTISEMENT This Week's Survey [Back Pain: Take Two Yoga Classes and Call Me Next Month?]( [The American College of Physicians issued an]([updated guideline on management of low back pain](, calling for non-drug treatments to be tried before resorting to medications. CME Spotlights [Gynecologic Cancers @Point of Care]( [Source: @Point of Care]( [MDS and Acute Myeloid Leukemia (MDS and AML) @Point of Care]( [Source: @Point of Care]( [Prostate Cancer @Point of Care]( [Source: @Point of Care]( [Skin Cancers @Point of Care]( [Source: @Point of Care]( [Are biosimilars as safe and effective as reference products?]( [Source: France Foundation]( [Playing The Offense In Advanced Basal Cell Carcinoma: A Team Approach To Treatment And Management]( [Source: RMEI Medical Education]( [Clinical Convergenceu2120: Patient and Provider Perspectives in NSCLC: Follow-up Visits]( [Source: RMEI Medical Education]( [Clinical Convergence℠: Patient and Provider Perspectives in NSCLC: Initial Visits]( [Source: RMEI Medical Education]( [Breast Cancer @POC w/Watson]( [Source: @Point of Care]( More of Today's Stories [iMedical Apps: CoherentRx for Asthma Patient Education]( [CLL Resistance Mutations Often Arise Early]( CME/CE [Overdiagnosis Is a Problem in Pediatrics, Too]( ['Ransomware' Attacks on Providers Still an Issue]( [Peritoneal Dialysis Safe for Post-Op Fluid Overload in Infants with CHD]( [Lotus Valve's Design Change Tied to Slowdown of PPM]( [Clinical Potential of Measuring Plasma Tumor DNA in Breast Cancer]( [Cancer Patients Skip Meds Due to High Costs]( CME/CE [CRT: Physicians Squabble Over Tricuspid Valve Technologies]( [Pelzman's Picks: GOP Rhetoric on ACA Grows More Nuanced]( [Wise Buy? Left Ventricular Assist Devices]( [Legalizing Gay Marriage: A Health Benefit for Kids?]( [Most Physicians Groups Pleased 'Gun Gag Law' Is Overturned]( ['Low T' Tx Studies Yield Mixed Findings for Heart]( [NeuroBreak: A Win for MS; Another Loss for Alzheimer's; $125M Voucher]( [1-Star vs 5-Star Docs: What's the Difference?]( [Benefits in Anemia, BMD with Testosterone Tx]( CME/CE [Agent that Targets GM-CSF Shows Promise in RA]( CME/CE [IBM Chief Proclaims 'Profoundly Hopeful' Era]( More news from MedPage Today® Meeting Coverage Can't get away? MedPage Today brings you extensive coverage of more than 80 meetings in a wide range of specialties. © 2016 Medpage Today, LLC. All rights reserved. Use of this site constitutes acceptance of the [MedPageToday.com]( [terms of use]( and [privacy policy](. The material on this site is for informational purposes only, and is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider. Medpage Today is located at 345 Hudson Street, New York, NY 10014 [Remove me from this list](lst=Daily%20Headlines) [Manage my e-mail settings](

Marketing emails from medpagetoday.com

View More
Sent On

08/12/2024

Sent On

08/11/2024

Sent On

07/11/2024

Sent On

07/11/2024

Sent On

06/11/2024

Sent On

04/11/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.